RU2017127484A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2017127484A3 RU2017127484A3 RU2017127484A RU2017127484A RU2017127484A3 RU 2017127484 A3 RU2017127484 A3 RU 2017127484A3 RU 2017127484 A RU2017127484 A RU 2017127484A RU 2017127484 A RU2017127484 A RU 2017127484A RU 2017127484 A3 RU2017127484 A3 RU 2017127484A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15154028.3 | 2015-02-05 | ||
| EP15154028.3A EP3053920B1 (en) | 2015-02-05 | 2015-02-05 | Compounds with anti-tumoral activity |
| PCT/EP2016/052523 WO2016124747A1 (en) | 2015-02-05 | 2016-02-05 | Compounds with anti-tumoral activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017127484A RU2017127484A (ru) | 2019-03-05 |
| RU2017127484A3 true RU2017127484A3 (enExample) | 2019-08-14 |
| RU2758259C2 RU2758259C2 (ru) | 2021-10-27 |
Family
ID=52450012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017127484A RU2758259C2 (ru) | 2015-02-05 | 2016-02-05 | Соединение формулы (I), фармацевтическая композиция, применение соединения формулы (I) для лечения гематологических и/или пролиферативных нарушений |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US10570122B2 (enExample) |
| EP (2) | EP3053920B1 (enExample) |
| JP (1) | JP6713000B2 (enExample) |
| KR (1) | KR102544132B1 (enExample) |
| CN (1) | CN107531685B (enExample) |
| AR (1) | AR103629A1 (enExample) |
| AU (1) | AU2016214283B2 (enExample) |
| BR (1) | BR112017016883B1 (enExample) |
| CA (1) | CA2975644C (enExample) |
| CY (1) | CY1124948T1 (enExample) |
| DK (1) | DK3253749T3 (enExample) |
| ES (2) | ES2796276T3 (enExample) |
| HR (1) | HRP20220114T1 (enExample) |
| HU (1) | HUE059063T2 (enExample) |
| IL (1) | IL253779A0 (enExample) |
| LT (1) | LT3253749T (enExample) |
| MX (1) | MX377742B (enExample) |
| PL (1) | PL3253749T3 (enExample) |
| PT (1) | PT3253749T (enExample) |
| RS (1) | RS62901B1 (enExample) |
| RU (1) | RU2758259C2 (enExample) |
| TW (1) | TWI748938B (enExample) |
| WO (1) | WO2016124747A1 (enExample) |
| ZA (1) | ZA201705537B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018106643A1 (en) * | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
| CN109467531A (zh) * | 2017-09-08 | 2019-03-15 | 沈阳科创化学品有限公司 | 一种取代吡啶二羧酸衍生物的制备方法 |
| CN112225733B (zh) * | 2020-11-25 | 2022-12-09 | 湖南科技大学 | 一种含1,3,4-噻二唑吡啶-2-酮衍生物的制备方法和作为抗癌药物的应用 |
| IL322886A (en) * | 2023-02-24 | 2025-10-01 | Ab Science | Compounds for the treatment of myeloid diseases with chromosomal abnormalities |
| CN117720459A (zh) * | 2023-12-26 | 2024-03-19 | 江苏希迪制药有限公司 | 一种阿贝西利中间体5-[(4-乙基哌嗪-1-基)甲基]吡啶-2-胺制备工艺 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US810665A (en) * | 1905-10-10 | 1906-01-23 | Joseph Mlada | Mold for butter. |
| US1346834A (en) * | 1918-08-17 | 1920-07-20 | Charles E Mcmanus | Resilient rod |
| US3740420A (en) | 1967-11-28 | 1973-06-19 | Crown Zellerbach Corp | Pharmaceutical compositions with dimethyl sulfoxide |
| US3743727A (en) | 1970-11-16 | 1973-07-03 | Crown Zellerbach Corp | Enhancing tissue penetration of certain antimicrobial agents with dimethyl sulfoxide |
| US4405616A (en) | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| CA1163561A (en) | 1979-11-06 | 1984-03-13 | Cyril Boroda | Preparation containing nitroglycerine and optionally other medicaments and preparation thereof |
| US4460372A (en) | 1981-02-17 | 1984-07-17 | Alza Corporation | Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer |
| US4379454A (en) | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
| US4411893A (en) | 1981-08-14 | 1983-10-25 | Minnesota Mining And Manufacturing Company | Topical medicament preparations |
| CA1236029A (en) | 1984-05-14 | 1988-05-03 | Edmund Sandborn | Pharmaceutical solutions comprising dimethyl sulfoxide |
| US4615699A (en) | 1985-05-03 | 1986-10-07 | Alza Corporation | Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes |
| DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
| GB9622363D0 (en) * | 1996-10-28 | 1997-01-08 | Celltech Therapeutics Ltd | Chemical compounds |
| US5906202A (en) | 1996-11-21 | 1999-05-25 | Aradigm Corporation | Device and method for directing aerosolized mist to a specific area of the respiratory tract |
| EP1146875A4 (en) * | 1998-12-07 | 2002-05-02 | Smithkline Beecham Corp | MYT1 KINASE INHIBITORS |
| JP4216947B2 (ja) * | 1999-05-18 | 2009-01-28 | 三井化学株式会社 | アミン化合物 |
| US8450302B2 (en) * | 2002-08-02 | 2013-05-28 | Ab Science | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| ATE375342T1 (de) * | 2002-08-02 | 2007-10-15 | Ab Science | 2-(3-aminoaryl)amino-4-aryl-thiazole und ihre verwendung als c-kit inhibitoren |
| CN102584813B (zh) * | 2003-05-14 | 2016-07-06 | Ngc药物公司 | 化合物及其在调节淀粉样蛋白β中的用途 |
| US7718676B2 (en) * | 2003-10-23 | 2010-05-18 | Ab Science | 2-aminoaryloxazole compounds as tyrosine kinase inhibitors |
| WO2006010637A2 (en) * | 2004-07-30 | 2006-02-02 | Gpc Biotech Ag | Pyridinylamines |
| CA2578122A1 (en) * | 2004-08-27 | 2006-03-02 | Gpc Biotech Ag | Pyrimidine derivatives |
| UA95071C2 (ru) * | 2005-04-04 | 2011-07-11 | Аб Сьянс | Замещенные производные оксазола и их применение как ингибиторов тирозинкиназы |
| BRPI0608910A2 (pt) * | 2005-05-09 | 2010-02-17 | Achillion Pharmaceuticals Inc | uso de um composto da fórmula ou um sal ou hidrato farmaceuticamente aceitável desse, composto ou sal ou hidrato do mesmo, composição farmacêutica e composição farmacêutica embalada |
| JP5214096B2 (ja) * | 2005-06-17 | 2013-06-19 | 富士フイルムファインケミカルズ株式会社 | 新規なビピリジン誘導体 |
| US20080207572A1 (en) * | 2005-07-14 | 2008-08-28 | Ab Science | Use of Dual C-Kit/Fgfr3 Inhibitors for Treating Multiple Myeloma |
| ES2632940T3 (es) * | 2005-09-13 | 2017-09-18 | Janssen Pharmaceutica Nv | Derivados de tiazol sustituidos con 2-anilin-4-arilo |
| GB0524436D0 (en) * | 2005-11-30 | 2006-01-11 | Novartis Ag | Organic compounds |
| EP2418202B1 (en) * | 2006-03-31 | 2014-01-29 | Novartis AG | (4-[4-[5-(substituted amino)-pyridin-2-yl]phenyl]-cyclohexyl)-acetic acid derivatives as DGAT inhibitors |
| JO3019B1 (ar) * | 2006-04-19 | 2016-09-05 | Janssen Pharmaceutica Nv | ثلاثي مستبدل 4،2،1-ثلاثي زولات |
| WO2007131953A1 (en) | 2006-05-12 | 2007-11-22 | Ab Science | A new process for the synthesis of 2-aminoxazole compounds |
| FR2901273B1 (fr) * | 2006-05-19 | 2010-12-24 | Anaconda Pharma | Inhibiteurs du virus du papillome humain et les compositions pharmaceutiques les contenant |
| MX2009007302A (es) * | 2007-01-23 | 2009-07-15 | Palau Pharma Sa | Derivados de purina. |
| BRPI0807637A2 (pt) * | 2007-02-22 | 2014-06-03 | Irm Llc | Derivados de tiazol como moduladores de receptores acoplados à proteína g |
| GB0709031D0 (en) * | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
| US8420695B2 (en) * | 2008-07-09 | 2013-04-16 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| JP2012180281A (ja) * | 2009-06-29 | 2012-09-20 | Dainippon Sumitomo Pharma Co Ltd | 新規オキサジアゾール誘導体 |
| CA2778517A1 (en) * | 2009-07-15 | 2011-01-20 | Janssen Pharmaceuticals, Inc. | Substituted triazole and imidazole derivatives as gamma secretase modulators |
| EP2499282B1 (en) * | 2009-11-09 | 2015-04-22 | NeuroGenetic Pharmaceuticals, Inc. | Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor |
| EA022188B1 (ru) * | 2010-01-12 | 2015-11-30 | Аб Сьянс | Оксазольные ингибиторы киназы, содержащие их композиции и их применение |
| GB201012105D0 (en) * | 2010-07-19 | 2010-09-01 | Domainex Ltd | Novel pyrimidine compounds |
| AU2011302216A1 (en) * | 2010-09-14 | 2013-04-04 | Exelixis, Inc. | Phtalazine derivatives as JAK1 inhibitors |
| WO2012068210A1 (en) * | 2010-11-18 | 2012-05-24 | Janssen Pharmaceutica Nv | Pyridyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation |
| US20120302569A1 (en) * | 2011-05-25 | 2012-11-29 | Paul Francis Jackson | Phenyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation |
| EP2714667B1 (en) * | 2011-05-27 | 2020-11-25 | Laxman S. DESAI | Aminooxazole inhibitors of cyclin dependent kinases |
| BR112014001977A2 (pt) | 2011-07-27 | 2017-02-21 | Ab Science | inibidores seletivos de proteína quinase |
| KR101896035B1 (ko) * | 2011-08-23 | 2018-09-07 | 덕산네오룩스 주식회사 | 유기전기소자용 신규 화합물, 이를 이용하는 유기전기소자 및 그 단말 |
| CN103436048B (zh) * | 2013-08-08 | 2014-12-03 | 陕西师范大学 | 硫脲供体双桥链有机染料及其应用 |
| US20150045353A1 (en) * | 2013-08-09 | 2015-02-12 | Neurogenetic Pharmaceuticals, Inc. | Formulations containing gamma secretase modulators, methods for preparation and delivery thereof |
| SG11201607525UA (en) * | 2014-03-24 | 2016-10-28 | Ab Science | Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors |
| EP3144307A1 (en) * | 2015-09-18 | 2017-03-22 | AB Science | Novel oxazole derivatives that inhibit syk |
-
2015
- 2015-02-05 ES ES15154028T patent/ES2796276T3/es active Active
- 2015-02-05 EP EP15154028.3A patent/EP3053920B1/en active Active
-
2016
- 2016-02-05 DK DK16703138.4T patent/DK3253749T3/da active
- 2016-02-05 PL PL16703138T patent/PL3253749T3/pl unknown
- 2016-02-05 AU AU2016214283A patent/AU2016214283B2/en active Active
- 2016-02-05 RS RS20220136A patent/RS62901B1/sr unknown
- 2016-02-05 HU HUE16703138A patent/HUE059063T2/hu unknown
- 2016-02-05 AR ARP160100337A patent/AR103629A1/es unknown
- 2016-02-05 ES ES16703138T patent/ES2905412T3/es active Active
- 2016-02-05 US US15/548,451 patent/US10570122B2/en active Active
- 2016-02-05 MX MX2017010157A patent/MX377742B/es active IP Right Grant
- 2016-02-05 BR BR112017016883-9A patent/BR112017016883B1/pt active IP Right Grant
- 2016-02-05 CN CN201680008641.9A patent/CN107531685B/zh active Active
- 2016-02-05 CA CA2975644A patent/CA2975644C/en active Active
- 2016-02-05 EP EP16703138.4A patent/EP3253749B1/en active Active
- 2016-02-05 TW TW105103940A patent/TWI748938B/zh not_active IP Right Cessation
- 2016-02-05 WO PCT/EP2016/052523 patent/WO2016124747A1/en not_active Ceased
- 2016-02-05 RU RU2017127484A patent/RU2758259C2/ru not_active Application Discontinuation
- 2016-02-05 KR KR1020177022077A patent/KR102544132B1/ko active Active
- 2016-02-05 HR HRP20220114TT patent/HRP20220114T1/hr unknown
- 2016-02-05 JP JP2017539023A patent/JP6713000B2/ja active Active
- 2016-02-05 PT PT167031384T patent/PT3253749T/pt unknown
- 2016-02-05 LT LTEPPCT/EP2016/052523T patent/LT3253749T/lt unknown
-
2017
- 2017-08-01 IL IL253779A patent/IL253779A0/en active IP Right Grant
- 2017-08-15 ZA ZA201705537A patent/ZA201705537B/en unknown
-
2022
- 2022-02-02 CY CY20221100089T patent/CY1124948T1/el unknown
Also Published As
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20191204 |
|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20200218 |